NCT02194985 - Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 14, 2015

Primary Completion Date

October 23, 2019

Study Completion Date

October 23, 2019

Conditions

Fabry Disease

Interventions

DRUG

migalastat HCl 150 mg

Migalastat HCl 150 mg (equivalent to 123 mg migalastat) was provided as capsules in blister packs. One capsule was taken orally every other day.

Trial Locations (28)

1090

Clinical Study Site, Vienna

2100

Clinical Study Site, Copenhagen

2650

Clinical Study Site, Edegem

3050

Clinical Study Site, Parkville

5000

Clinical Study Site, Adelaide

10016

Clinical Study Site, New York

11451

Clinical Study Site, Cairo

22030

Clinical Study Site, Fairfax

30322

Clinical Study Site, Atlanta

49525

Clinical Study Site, Grand Rapids

50134

Clinical Study Site, Florence

59037

Clinical Study Site, Lille

66160

Clinical Study Site, Kansas City

75226

Clinical Study Site, Dallas

92380

Clinical Study Site, Garches

97239

Clinical Study Site, Portland

B1629ODT

Clinical Study Site, Pilar

90035-903

Clinical Study Site, Porto Alegre

H4J 1C5

Clinical Study Site, Montreal

00168

Clinical Study Site, Roma

565-0871

Clinical Study Site, Suita

951-8520

Clinical Study Site, Niigata

545-8586

Clinical Study Site, Osaka

105-8471

Clinical Study Site, Tokyo

08025

Clinical Study Site, Barcelona

06500

Clinical Study Site, Ankara

NW3 2QG

Clinical Study Site, London

WC1N3BG

Clinical Study Site, London